From New Board Appointment Ann. IMO, Dr Paul up-beat, good and positive on the Co.
Dr Paul Kasian commented “The company is extremely happy to welcome Mr Burrows to the boardgiven his wealth of experience, in assisting companies in both commercialization of opportunities andcorporate governance, in what is a very exciting time for the company.”
From the Preliminary Final Report p2. GTG’s first-to-market genetic risk assessment test for colorectal cancer is also now launched. This is the first of asuite of ground-breaking new products GTG will deliver in the next 12 months.
Further genetic risk assessment tests under development: • Cardiovascular Disease - target launch late 2019 • Type 2 Diabetes - target launch late 2019 • Prostate Cancer - 2020• Melanoma - 2020
Got to like them apples. Rome wasn't built in a day... .
GTG Price at posting:
0.6¢ Sentiment: Buy Disclosure: Held
